News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hutchison China MediTech (Chi-Med) in Partner Talks for Cancer Drug


5/10/2013 9:15:10 AM

by Richard Daverman, PhD

May 9, 2013 -- Hutchison Chi-Med expects to license global rights to fruqintinib, one of its novel small-cell cancer drugs, before year-end, according to CEO Christian Hogg. The company has been in due diligence discussions with potential partners, he added. Because the drug is a promising treatment for solid tumors, Chi-Med will conduct simultaneous clinical trials against several types of cancer, and the company wants a partner to help shoulder the financial burden. More details....

Stock Symbol: (AIM: HCM)


Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES